EAErwin G. Abucayon

Erwin G. Abucayon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Erwin G. Abucayon has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Gary R. Matyas

    U.S. Military HIV Research Program, Center for Infectious Diseases Research, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA

    2 shared publications
  • Adrian Carreon

    Henry M. Jackson Foundation for the Advancement of Military Medicine, 6720A Rockledge Drive, Bethesda, Maryland 20817, USA

    1 shared publication
  • Agnieszka Sulima

    Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Department of Health and Human Services, 9800 Medical Center Drive, Bethesda, MD 20892, USA

    1 shared publication
  • Arthur E. Jacobson

    Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Department of Health and Human Services, 9800 Medical Center Drive, Bethesda, MD 20892, USA

    1 shared publication
  • C. Steven Godin

    Inotiv, 13 Firstfield Rd., Suite 110, Gaithersburg, MD 20878, USA

    1 shared publication
  • Cierra Rochelle

    Henry M. Jackson Foundation for the Advancement of Military Medicine, 6720A Rockledge Drive, Bethesda, Maryland 20817, USA

    1 shared publication

Latest Publications

  • Open Access

    Red blood cells as probes for determining free QS21 in liposomal adjuvant formulations to support product safety and stability

    by Essie Komla, Cierra Rochelle, Adrian Carreon, Oscar B. Torres, Gary R. Matyas, Erwin G. Abucayon

    Analytical method development is critical to establishing and supporting drug product quality. QS21 is a potent adjuvant, which is currently used in several clinical vaccine trials, and is utilized as an adjuvant in licensed vaccines against malaria, shingles and respiratory syncytial virus (RSV). Due to its toxic and hemolytic properties as a stand-alone or free adjuvant, QS21 has been incorporated into heterogeneous matrices containing cholesterol that serve as QS21 sinks to suppress its toxic activity. Hence, to address the safety attribute of the QS21-based adjuvant, it is imperative to ensure the absence of free QS21 in the drug formulation. To date, quantitative analytical methods that definitively discriminate free from bound QS21 in liposomal adjuvant formulations are not available in the literature. In view of this, we have developed and qualified a cell-based assay using human red blood cells (RBCs) as probes for detecting and estimating free QS21 in liposomal formulations. This method exhibits a medium throughput, and does not require any expensive and special instrumentation system. Qualification results showed that the method presents good specificity for free QS21 detection, accuracy and precision, with quantitation sensitivity in the micromolar range (lower limit of ∼25 μg mL−1), suitable for our intended purpose. The described method was successfully used as part of the regulatory specification tests for the product release and stability studies of Army Liposome Formulation containing QS21 (ALFQ).

  • Open Access

    Safety and Toxicology Profile of TT-6-AmHap Heroin Conjugate Vaccine

    by Essie Komla, Erwin G. Abucayon, C. Steven Godin, Agnieszka Sulima, Arthur E. Jacobson, Kenner C. Rice, Gary R. Matyas

    Background/Objectives: Opioid use disorder (OUD) remains a severe health problem globally, resulting in substantial social and economic challenges. While existing medications for managing OUD are proven to be effective, they also present certain challenges. A vaccine offers a promising therapeutic strategy to combat OUD and potentially reduce the risk of overdose death. The TT-6-AmHap heroin conjugate vaccine has effectively reduced heroin-induced pharmacological effects in behavioral assays as well as demonstrated the induction of high titer and high affinity antibody responses in mice and rats. In this GLP study conducted in rabbits, the potential local and systemic toxicity of the TT-6-AmHap heroin vaccine in combination with or without adjuvants ALF43 and Alhydrogel® (ALFA) was investigated. Methods: Male and female New Zealand White rabbits were administered with vaccines or a saline control intramuscularly at two-week intervals over a 57-day study period. The presence, persistence or reversibility of any toxic effects of the vaccine was determined over a four-week recovery period. Results: Administration of TT-6-AmHap with or without the adjuvants induced high antibody-specific IgG in treatment groups compared to the controls. The study found no TT-6-AmHap-related effects on mortality, physical examinations, dermal Draize observations, body weights, body weight changes, food consumption, ophthalmology, clinical pathology (hematology, coagulation, clinical chemistry, and urinalysis), macroscopic pathology, or organ weights. Conclusions: Under the conditions of this study, these results demonstrate that the TT-6-AmHap vaccine with or without adjuvants was well tolerated, immunogenic, and the effects were not considered adverse in both male and female rabbits.